The US FDA updated Compliance Program CP 7382.850 on 2 February 2026, expanding inspections to a Total Product Life Cycle (TPLC) approach. The program aligns with QMSR (21 CFR 820) incorporating ISO 13485:2016 and emphasizes UDI, labeling, tracking, reporting, and postmarket surveillance. Manufacturers and importers must review quality systems, registration, and TPLC compliance to meet inspection and enforcement expectations.
On 2 February 2026, the US Food and Drug Administration (FDA) released an updated Compliance Program Manual (CP 7382.850) for the inspection of medical device manufacturers. This update coincides with the implementation of the Quality Management System Regulation (QMSR), which now incorporates ISO 13485:2016 by reference, marking a significant step toward regulatory convergence for medical device quality systems.
The new Compliance Program supersedes previous guidance and expands the FDA’s inspection scope to include a Total Product Life Cycle (TPLC) assessment, covering devices from design and development through postmarket surveillance.
Total Product Life Cycle (TPLC) Approach
Under the updated CP, FDA inspections will now assess compliance across the entire product life cycle, including:
This TPLC approach emphasizes that manufacturers and importers are responsible for maintaining regulatory compliance at every stage of the device lifecycle.
The QMSR (21 CFR 820) now references ISO 13485:2016, providing FDA field staff and manufacturers with a framework for harmonised quality system requirements. This alignment helps manufacturers prepare for global regulatory expectations and supports international convergence in device quality management practices.
The updated CP emphasizes the importance of Unique Device Identification (UDI) compliance, ensuring that devices are adequately identified from manufacturing through distribution. Manufacturers and importers must maintain traceability and accurate device identification to support:
CP 7382.850 provides detailed instructions to FDA field and Center staff regarding inspections and enforcement related to:
The CP also incorporates considerations for manufacturers participating in the Medical Device Single Audit Program (MDSAP), linking audit findings to regulatory compliance oversight.
Manufacturers and importers should be aware that:
To prepare for inspections under CP 7382.850, manufacturers and importers should:
Early adoption and internal verification will help minimize inspection findings and enforcement actions.
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us